

Axillary Hyperhidrosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/AB319BF316EEN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: AB319BF316EEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Axillary Hyperhidrosis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Axillary Hyperhidrosis Understanding

Axillary Hyperhidrosis: Overview

Axillary hyperhidrosis, or excessive underarm sweating, is a common condition affecting up to 3% of the population. Axillary hyperhidrosis usually starts in childhood or adolescence but some people first experience it as adults. The impact of this condition is often underestimated – it can affect work and social situations and may cause significant psychological distress. Fortunately, effective treatments are readily available. Hyperhidrosis symptoms can range widely in their severity and impact on your life. Minor symptoms may ebb and flow over a long time. Or excessive sweating may be an everyday challenge, a constant source of frustration and insecurity.

'Axillary Hyperhidrosis - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axillary Hyperhidrosis pipeline landscape is provided which includes the disease overview and Axillary Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Axillary Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axillary Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Axillary Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Axillary Hyperhidrosis.

Axillary Hyperhidrosis Emerging Drugs Chapters

This segment of the Axillary Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axillary Hyperhidrosis Emerging Drugs

Umeclidinium: GlaxoSmithKline

Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of M3 receptor at the smooth muscle leading to bronchodilation. Currently, it is in Phase II stage of development to treat Axillary Hyperhidrosis.

Meditoxin: Medytox

Meditoxin, also known as Botulinum toxin A is developed by Medytox. It is an Acetylcholine inhibitor. Currently, it is in Phase III stage of development to treat Axillary Hyperhidrosis.

Further product details are provided in the report.....

Axillary Hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Axillary Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Axillary Hyperhidrosis

There are approx. 3+ key companies which are developing the therapies for Axillary Hyperhidrosis. The companies which have their Axillary Hyperhidrosis drug candidates in the most advanced stage, i.e. phase II include, GlaxoSmithKline.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intradermal

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axillary Hyperhidrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axillary Hyperhidrosis therapeutic drugs

key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axillary Hyperhidrosis drugs.

Axillary Hyperhidrosis Report Insights

Axillary Hyperhidrosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Axillary Hyperhidrosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Axillary Hyperhidrosis drugs?

How many Axillary Hyperhidrosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axillary Hyperhidrosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axillary Hyperhidrosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Axillary Hyperhidrosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

GlaxoSmithKline

Medytox

Theravida

Candesant Biomedical

Key Products

Umeclidinium

Meditoxin

THVD-102

Contents

Introduction

Executive Summary

Axillary Hyperhidrosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Meditoxin: Medytox

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Umeclidinium: GlaxoSmithKline

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Axillary Hyperhidrosis Key Companies
Axillary Hyperhidrosis Key Products
Axillary Hyperhidrosis- Unmet Needs
Axillary Hyperhidrosis- Market Drivers and Barriers
Axillary Hyperhidrosis- Future Perspectives and Conclusion
Axillary Hyperhidrosis Analyst Views
Axillary Hyperhidrosis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Axillary Hyperhidrosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Axillary Hyperhidrosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Axillary Hyperhidrosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/AB319BF316EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AB319BF316EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970